Stada Group
Ann-Sophie Vondung has a work experience that includes various roles at different companies. From April 2018 to February 2019, they worked at the STADA Group as a Senior Manager QA, responsible for the final inspection of finished products. In March 2019, they temporarily took on the position of Head of Centralized Release Services. Then, in June 2019, they were promoted to Director of Global Quality Operations at STADA Group. Prior to this, from April 2015 to March 2018, Ann-Sophie worked at Pfizer as a Manager QC and Deputy Head of QK.
Ann-Sophie Vondung completed their Staatsexamen in Pharmazie at The Philipp University of Marburg.
This person is not in any offices
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.